Saving Lives Through
Innovative Molecular
Diagnostic Solutions

Early identification of Cancer saves lives.

To be effective, sample collection needs to be simple, readily available, and affordable.

We develop innovative products and product candidates that quickly and easily identify the early onset of several leading deadly conditions – such as colorectal (“CRC”) and pancreatic cancer.

Our goal is to place effective solutions where they need to be… In your hands.

Mainz BioMed (NASDAQ: MYNZ) – founded in Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.

Mainz BioMed (NASDAQ: MYNZ) develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

Clinical laboratory tests save time, costs and lives by enabling early detection and prevention of disease.

Patients with cancers and other conditions are living longer and enjoying better health because of a medical revolution in diagnostic technology.

At its center are genetic and genomic tests that identify the unique genetic profile of individual patients or their disease and allow physicians to tailor treatment to those unique characteristics.

OUR COMPANY

OUR BUSINESS

OUR SOLUTION

LATEST NEWS

  • All
  • Corporate News
  • Events
  • Media
  • Presentations
  • Recruitment
All
  • All
  • Corporate News
  • Events
  • Media
  • Presentations
  • Recruitment
Corporate News

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Corporate News

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

Corporate News

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.

  • This field is for validation purposes and should be left unchanged.